By Sriparna Roy and Bhanvi Satija (Reuters) -Shares of global vaccine makers were muted on Tuesday as investors and analysts ...

By Sriparna Roy and Bhanvi Satija (Reuters) -Shares of global vaccine makers were mixed on Tuesday, as investors assessed U.S ...

The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it ...

Vaccine maker stocks are steady despite RFK Jr.'s decision to fire all members of the CDC expert panel on immunizations. Read ...

BioNTech is buying fellow German mRNA vaccine developer CureVac in all-stock transaction that values the acquired biotech at ...

Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed ...

A fired committee member who served on the panel since July 2024 said the decision to fire him and his colleagues came from ...

Moderna vaulted to the forefront of biotech, becoming a major pillar of the region’s economy. But Robert F. Kennedy Jr.’s ...

The new appointees include Vicky Pebsworth, a regional director for the National Association of Catholic Nurses, who has been ...